Loading market movers...

panitumumab

Phase 2

Verastem, Inc. (VSTM)

00%

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jun '27

VSTMPhase 2$362M

panitumumab Phase 2 Est. Readout

panitumumab• Colorectal Cancer150

Jun 2027~Confirmed

00%

Competitive Landscape

5 competitors in Colorectal Cancer

SLDBFrog Bacterium Therapy

ETST[18F]FPyQCP

CLTS[18F]FPyQCP

BNTXautogene cevumeran

View Full Landscape

Drug Information

Target Indication

Colorectal Cancer

Clinical Trial

Last updated: 7/8/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

VSTM

Verastem, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

avutometinibPhase 3

Low Grade Serous Ovarian Cancer

avutometinib (VS-6766)Phase 2

Low Grade Ovarian Serous Adenocarcinoma

avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxelPhase 2

KRAS Activating Mutation

Avutometinib (VS-6766) + Defactinib (VS-6063)Phase 2

Low Grade Serous Ovarian Cancer

Pancreatic Ductal Adenocarcinoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts